drugset / Trial / NCT00093730
BMS-599626 in Treating Patients With Metastatic Solid Tumors
Phase 1
Completed
9 enrolled
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: BMS-599626 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of BMS-599626 in treating patients with metastatic solid tumors.
Timeline
- Start
- 2004-08
- Primary completion
- 2006-04
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-59926 | Unknown | — | Oral |